TICKERNERD
Menu
CRBPCRBPHealthcare · Biotechnology

CRBP Stock Forecast: Corbus Pharmaceuticals Holdings, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$8.12
−1.46% on the day

The 10 Wall Street analysts covering Corbus Pharmaceuticals Holdings, Inc. hold a median 12-month price target of $34 — +318.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$157.1M
Ticker Nerd rank
23 / 100
Median analyst target
$34
Analysts covering
10
Revenue$0.0
Operating income−$36.2M
Net income−$35.0M
Free cash flow−$29.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−29.1%
1M
−14.6%
YTD
−0.2%
1Y
−14.5%
From 52W high
−58.1%
From 52W low
+10.0%
$7
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRBP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Corbus Pharmaceuticals Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
76
Size
71
Quality
47
Momentum
43
Volatility
29
Value
29
Revisions
28
Growth
17
Issuance
14

Accruals (76): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRBP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRBP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26CRBPHigh $48Median $34Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $17Median $34High $48

The green dot is the last close — the median target sits +318.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
7 Aug 2026HC Wainwright & Co.MaintainsBuy$40 → $35
7 Aug 2026OppenheimerMaintainsOutperform$52 → $48
23 June 2026MizuhoMaintainsOutperform$44 → $34
23 June 2026MizuhoMaintainsOutperform—
17 June 2026OppenheimerMaintainsOutperform$54 → $52
17 June 2026OppenheimerMaintainsOutperform—
27 May 2026WedbushMaintainsOutperform—
26 May 2026HC Wainwright & Co.ReiteratesBuy—
22 May 2026MizuhoMaintainsOutperform—
13 May 2026GuggenheimReiteratesBuy—
13 May 2026JefferiesMaintainsBuy—
13 May 2026OppenheimerMaintainsOutperform—
29 Apr 2026GuggenheimInitiatesBuy—
10 Mar 2026OppenheimerMaintainsOutperform—
13 Nov 2025RBC CapitalMaintainsOutperform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025WedbushMaintainsOutperform—
17 Sept 2025HC Wainwright & Co.ReiteratesBuy—
6 Aug 2025OppenheimerMaintainsOutperform—
7 May 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRBP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRBP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Corbus Pharmaceuticals Holdings, Inc. returned −14.5% against +17.5% for the S&P 500, dividends included.

CRBP vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26CRBPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRBP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
9
Fundamentals

Corbus Pharmaceuticals Holdings, Inc. (CRBP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
1.5×

Cheaper than 56% of US stocks

EV / EBITDA
−0.4×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−95.6%

Higher than 14% of US stocks

Return on assets
−53.0%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Corbus Pharmaceuticals Holdings, Inc. (CRBP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Corbus Pharmaceuticals Holdings, Inc. has a market value of $157.1M and an enterprise value of $43.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$101.9M.

  • Diluted earnings per share, trailing twelve months: $−6.19.

  • Free cash flow in the twelve months to 30 June 2026: −$86.7M.

  • Shares outstanding: 17.7M.

  • Trailing P/E: −1.4×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Corbus Pharmaceuticals Holdings, Inc. employs 36 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CRBP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRBPCorbus Pharmaceuticals Holdings, Inc.$157.1M
23
HUMAHumacyte, Inc.$153.0M
17
MENSJyong Biotech Ltd.$147.7M
3
SPRBSpruce Biosciences, Inc.$154.3M
27
IMUXImmunic, Inc.$155.6M
34
CDXSCodexis, Inc.$157.6M
64
NRXPNRX Pharmaceuticals, Inc.$142.6M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Corbus Pharmaceuticals Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRBP news & analysis

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

GlobeNewsWire · 11 Sept 2026neutral

Corbus Pharmaceuticals announced it will host a virtual webcast conference call on Monday, September 14, 2026, at 8:00 AM EDT to discuss topline data from its CANYON-1 clinical trial and the potential of CRB-913 in obesity.

Why it matters — CRBP watchers would care because the upcoming call is expected to present topline data from the CANYON-1 trial and a discussion of CRB-913's potential in obesity, which are key developments for the company.

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 17 Aug 2026neutral

Corbus Pharmaceuticals granted inducement equity awards to Leonardo Nicacio upon his commencement as Chief Medical Officer. The grants, approved by the Compensation Committee effective August 16, 2026, were made outside the company's stockholder-approved equity plans in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — A CRBP watcher would care because the company is bringing on a new Chief Medical Officer with an equity inducement package, signaling a leadership addition as Corbus advances its oncology and obesity programs.

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

GlobeNewsWire · 4 Aug 2026positive

Corbus Pharmaceuticals announced the last patient has completed their final visit in the CANYON-1 Phase 1b trial of CRB-913 for obesity, with topline data expected in September 2026. The study follows a Phase 1a trial that showed differentiated gastrointestinal tolerability compared to GLP-1 class drugs.

Why it matters — The completion of patient visits brings Corbus a step closer to topline data for CRB-913, which showed promising tolerability and significantly lower brain penetration than monlunabant in earlier studies.

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

GlobeNewsWire · 28 July 2026positive

Corbus Pharmaceuticals announced FDA clearance to initiate the TEMPO-1 registrational study of CRB-701 in patients with second-line oropharyngeal squamous cell carcinoma (OPSCC), with enrollment expected to begin in September 2026.

Why it matters — This FDA clearance allows Corbus to advance CRB-701, a next-generation Nectin-4 ADC, into a registrational study for a common head and neck cancer with approximately 14,000 eligible US patients annually.

FAQ

Frequently asked questions about CRBP stock

What is the CRBP stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Corbus Pharmaceuticals Holdings, Inc. have a median 12-month price target of $34, with estimates ranging from $17 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRBP stock a buy right now?

Of the 10 analysts covering Corbus Pharmaceuticals Holdings, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Corbus Pharmaceuticals Holdings, Inc. 23 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRBP?

As at 12 Sept 2026, Corbus Pharmaceuticals Holdings, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (76 of 100).

Will CRBP stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +318.7% from the last close, and Ticker Nerd's factor model ranks Corbus Pharmaceuticals Holdings, Inc. 23 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRBP stock forecast for 2030?

No analyst covering Corbus Pharmaceuticals Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRBP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $48 over the next 12 months.

How has CRBP stock performed over the past year?

Corbus Pharmaceuticals Holdings, Inc. returned -14.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Corbus Pharmaceuticals Holdings, Inc. do?

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity.

What is the latest news on CRBP?

The most recent item we track (GlobeNewsWire, 11 Sept 2026): "Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity". Corbus Pharmaceuticals announced it will host a virtual webcast conference call on Monday, September 14, 2026, at 8:00 AM EDT to discuss topline data from its CANYON-1 clinical trial and the potential of CRB-913 in obesity.

Company

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity. Corbus Pharmaceuticals Holdings, Inc. advances a pipeline centered on targeted treatments, including CRB-701, an antibody drug conjugate designed to target Nectin-4 on cancer cells, and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist being studied for obesity. The company’s work is concentrated on well-defined biological pathways and on creating medicines that address serious diseases through precision-focused mechanisms. Corbus Pharmaceuticals Holdings, Inc. plays a role in the biotechnology market as a developer of investigational drug candidates aimed at cancer and metabolic disease, with its current programs spanning clinical research and product development in these therapeutic areas.

CEO Dr. Yuval Cohen Ph.D. · 36 employees · United States · https://www.corbuspharma.com